We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-15.91 | -2.10% | 740.00 | 745.00 | 730.34 | 743.10 | 4,593,881 | 01:00:00 |
By Angela Chen
Novartis AG's Entresto drug has been approved by the U.S. Food and Drug Administration for the treatment of heart failure.
The FDA's decision is based on a study that enrolled nearly 8,5000 patients. The study ended early when it showed that Entresto "significantly" reduced the risk of death when compared with a treatment called enalapril, according to the Swiss pharmaceutical company.
The treatment, also known as sacubitril/valsartan, is usually prescribed alongside other heart failure therapies for patients with reduced ejection fraction, meaning their heart muscle that doesn't contract effectively.
Entresto is undergoing review in several countries and, if approved, could have sales of more than $5 billion, Novartis said.
It added that nearly six million people in the U.S. have heart failure, of which about half have the form with reduced ejection fraction.
Novartis most recently reported a rise in first-quarter earnings, after it closed deals with GlaxoSmithKline and Eli Lilly and Co.
Write to Angela Chen at angela.chen@dowjones.com
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=CH0012005267
Access Investor Kit for Eli Lilly & Co.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US5324571083
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US66987V1098
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions